YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Braveheart Bio, Inc. SAN FRANCISCO, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other…
The past several years saw muted IPO activity, a generally negative signal for market health. But 2026 has reversed that trend. Yes, you can say that the June IPO of SpaceX, the largest ever public offering, which raised over $85 billion i…
Key Points Interested in Braveheart Bio, Inc.? Here are five stocks we like better. Insiders are heavily buying speculative pharma stocks in the third quarter, signaling confidence. Braveheart Bio and BlossomHill Therapeutics are early-sta…
Deere upgraded, Lumentum initiated: Wall Street's top analyst calls The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by…
Investing.com -- Jefferies initiated coverage of Braveheart Bio with a Buy rating and a $48 price target, implying roughly 75% upside from the stock's prior closing price. The move comes after the company priced its initial public offering…
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Braveheart Bio (NasdaqGM: BRVE) completed its IPO and listed on the Nasdaq Global Market, with trading commencing before 11…
Rickey James Paul, Chief Financial Officer of Braveheart Bio, Inc. (NASDAQ:BRVE), reported an acquisition of 27,777 shares on August 7, 2026. SEC Form 4 filing. Company snapshot Braveheart Bio, Inc. (NASDAQ:BRVE) Market close (August 7, 20…
Director Christopher Viehbacher purchased 83,333 shares of Braveheart Bio, Inc. (NASDAQ:BRVE) at $18.00 per share on August 7, 2026, according to a recent SEC Form 4 filing. Transaction summary Metric Value Shares purchased 83,333 Transact…
Travis Murdoch, CEO and President, executed a direct purchase of 83,333 shares of Braveheart Bio, Inc. (NASDAQ:BRVE) on August 7, 2026. SEC Form 4 filing. Transaction summary Metric Value Transaction value $1.5 million Shares purchased 83,…
SAN FRANCISCO, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other serious cardiovascular…
[IPO Initial Public Offering on Financial Stock Market Chart 3D render] gonin Braveheart Bio (BRVE [https://seekingalpha.com/symbol/BRVE]), a clinical-stage drug developer focused on cardiovascular diseases, made a strong public debut on T…
SAN FRANCISCO, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other serious cardiovascular…
[Wall Street New York stock exchange stock market] alexsl Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week. M…